This phase I/II nonrandomized, open-label study was designed to assess the safety and benefit of sequencing irinotecan (Camptosar, CPT-11) plus paclitaxel (Taxol) immediately after cisplatin (Platinol)/etoposide (VePesid,
Daniel A. Rushing, MD
Advertisement
Articles by Daniel A. Rushing, MD
Advertisement
Latest Updated Articles
- Phase I/II Study of Weekly Irinotecan and Paclitaxel in Patients With SCLC
Published: July 2nd 2000 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC
2
177Lu-PSMA-I&T/223Ra Display Safety and Feasibility in Metastatic CRPC
3
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC
4
H.R. 2541: Examining Its Legislative Impact on Radiopharmaceutical Practice
5
